Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


BrainZ Business UpdateUS FDA Clearance sought

9 June 2006

BrainZ Business UpdateUS FDA Clearance sought for Seizure Detection Algorithm

BrainZ Instruments Limited (ASX:BZI) today announced it has lodged a submission with the United States Food and Drug Administration (“FDA”) for its computerassisted seizure detection algorithm1. The BrainZ computerassisted seizure detection algorithm will assist clinical staff to detect seizure activity in “at risk” infants in the Neonatal Intensive Care Unit. It will be sold as an upgrade to new and existing BrainZ BRM2 bedside brain monitor customers.

BrainZ CEO Dr Justin Vaughan says that “This additional sophistication to the BRM2 capability further differentiates the BrainZ technology and adds a muchneeded and highly valued additional resource for those clinicians and support staff involved in managing at risk infants.”
BRM2 monitors are currently in use in 16 countries around the world, mainly within Neonatal Intensive Care Units. In Australia, units retail for $25,000. BrainZ reported halfyearly sales growth of 29% in its most recent investor update.

“Over the past quarter we have experienced strong sales growth and the seizure detection capability feature will further increase the BRM2’s desirability catalysing further growth for BrainZ.

In terms of worldwide sales, the past three months has seen 31 BRM2 monitor sales compared to 25 in the previous six months and 5 in the same period last year. The sales delivered in the last quarter include our first into South Africa, which is a market of considerable potential,” Dr Vaughan added.

The BRM2 offers valuable insights into the neurological status of at risk infants and affords clinical staff better information upon which to base patient management and treatment decisions. There is limited but active competition to the BrainZ BRM2 in neonatal intensive care units but none of the available competition is able to provide any form of automated seizure detection capability. The addition of the computerassisted seizure detection algorithm to the BRM2 would provide an immediate additional point of difference over the current competition.

Dr Vaughan stated, “The addition of a seizure alarm system adds significant clinical utility to the BRM2 monitor and considerably enhances the value proposition to our customers. It is a quantum leap in terms of technology advancement. Also, the seizure detection method provides BrainZ with a core technology platform to springboard into wider markets, including adult areas.”

510(k) PreMarket Notification is being sought

The data supporting the seizure detection algorithm has been presented at multiple international medical conferences over the past 18 months. The data presented indicated that the BrainZ seizure detection algorithm had higher sensitivity, higher positive predictive value, higher correlation, and a lower level of false positive detection than two other recognized seizure detection algorithms. The latest presentation was made to the Pediatric Academic Societies’ meeting in San Francisco in May 2006.

Dr Vaughan states that “The data behind the seizure detection system is extremely robust, particularly its low rates of false positive detection which is critical for effective use within the intensive care environment.

The fact that many of the world’s leading neonatal units are lining up to trial the algorithm is testament to the attractiveness of the technology and the buzz associated with it throughout the international community. The process from here is that we shall select leading centres for beta testing of the seizure detection system and aim for full commercial release in the fourth quarter of 2006.”

Dr Vaughan advised that BrainZ had recently completed an extensive survey of all Australasian neonatal customers. 100% of respondents indicated that the BRM2 monitor was benefiting the management, treatment and care of their neonatal patients.

About BrainZ Instruments Limited: BrainZ is a New Zealand based medical device company specialising in bedside brain monitoring technology. BrainZ listed on the ASX in December 2005. BrainZ has filed for patent protection of the novel methodology behind the seizure detection system in multiple international territories.

About FDA 510k: Section 510(k) of the US Food, Drug and Cosmetic Act requires device manufacturers to notify FDA, at least 90 days in advance, of their intent to market a medical device. This is known as Premarket Notification also called PMN or 510(k). It allows FDA to determine whether the device is equivalent in terms of safety and effectiveness to a legally marketed device.

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>

ALSO:

Half A Billion Accounts: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>

Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>

ALSO:

Half Full: Fonterra Raises Forecast Payout As Global Supply Shrinks

Fonterra Cooperative Group, the dairy processor which will announce annual earnings tomorrow, hiked its forecast payout to farmers by 50 cents per kilogram of milk solids as global supply continues to decline, helping prop up dairy prices. More>>

ALSO:

Results:

Meat Trade: Silver Fern Farms Gets Green Light For Shanghai Maling Deal

The government has given the green light for China's Shanghai Maling Aquarius to acquire half of Silver Fern Farms, New Zealand's biggest meat company, with ministers satisfied it will deliver "substantial and identifiable benefit". More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news